CA-LIQUID-INSTRUMENTS
23.3.2021 14:02:04 CET | Business Wire | Press release
Today, Liquid Instruments , an innovator in precision software-defined instrumentation, launched Moku:Go , a complete, portable platform designed to bring the engineering lab anywhere and usher in a new era of scientific and engineering education at universities around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005031/en/
Within higher education, current in-person lab instrumentation is stationary, expensive, hardware-limited and fixed at the time of purchase. Existing portable solutions lack the intuitive software interfaces that current and future generations of students have come to expect. They also do not offer all of the necessary instruments and features to enable students to learn effectively outside of the lab. The increasing demand for remote learning solutions and a more hands-on experience both in and out of the classroom has fueled the market need for student-owned, flexible platforms that can support the next generation of engineers and scientists.
The new software-enabled hardware platform, Moku:Go, is an engineering lab that can fit in a backpack. It was designed for maximum portability, flexibility and durability, to take not just electrical engineering students, but physics, bioengineering, chemical engineering and other majors through all four years of their education and even beyond. It starts with 8 proven, powerful instruments including an oscilloscope, PID controller, logic analyzer, arbitrary waveform generator, data logger, spectrum analyzer, and more. It also features full connectivity with a Wi-Fi hotspot and USB-C, robust hardware features and electrical protection to ensure that students can explore new projects without putting themselves or their equipment at risk. The unique integrated power supplies are user programmable with high voltage and high current options for any project.
“Our students were thrilled when we first added Moku:Lab to our classroom two years ago, and after seeing the new capabilities of Moku:Go, I’m even more excited. It is clear that it will help take students’ educational experience into the modern era,” said Colonel Brian J. Neff, Electrical & Computer Engineering Department Head at the United States Air Force Academy. “I look forward to seeing this become a standard part of our curriculum.”
Moku:Go’s software was designed to appeal to a generation that is accustomed to intuitive user interfaces and broad compatibility. Liquid Instruments is bringing the user experience out of the flip-phone era and has designed intuitive Windows and Mac interfaces that are inviting and powerful for students. It offers remote access capabilities and clearly diagrammed views of the signal processing chain, which makes it easy for students to learn difficult concepts whether they are in person or remote. The student-centric design ensures they are learning the core concepts, rather than just learning the equipment itself.
Not only does Moku:Go help increase student engagement, but incorporation into curriculum also reduces faculty and teaching assistant workloads. The platform supports Python, LabVIEW and MATLAB APIs and has published examples of MATLAB live scripts for remote instruction, live student assistance and plagiarism control.
Its robust feature set and sophisticated software can also unlock advanced capabilities for makers and even high school students looking to explore engineering. Whether they are learning the basics of resistors and op-amps or designing an advanced quadcopter with sensors and autonomous navigation, Moku:Go enables easier access to otherwise complex concepts and hands-on engineering projects anytime, anywhere at an affordable price.
Liquid Instruments is introducing Moku:Go for science and engineering students as part of its growing product portfolio of high-precision instrumentation solutions developed by its team of experimental physicists and engineers that know firsthand what is necessary to transform the way learning and research is performed at all levels. The existing product, Moku:Lab, has been utilized for years by top institutions worldwide, enabling breakthrough research in the areas of photonics, electronics, and materials science.
“Our first product, Moku:Lab, gave R&D scientists the power and flexibility they needed to do their job, all in a streamlined and cost-effective platform. Now with Moku:Go we will bring those same advantages to improve the overall quality of education and motivate students to study science and engineering,” said Professor Daniel Shaddock, CEO and co-founder of Liquid Instruments. “Students deserve lab equipment that is powerful and flexible, but also simple and fun to use. Improving access to critical educational tools will empower students from all walks of life to pursue a career in STEM.”
Moku:Go starts at $499 and can be customized to match school colors, with volume purchasing for educational institutions. For information on education discounts, accessories and full specifications, please visit the product page here .
For more information about Liquid Instruments and its full suite of products, please visit https://liquidinstruments.com .
About Liquid Instruments
Liquid Instruments is a leader in precision software-defined instrumentation and is revolutionizing the way that scientists, engineers, and students expand their knowledge and conduct research & development. Their product line of hardware and software solutions leverages the computational power of modern FPGAs to create highly customizable instrumentation for controlling experiments and acquiring and analyzing data. The team’s IP in software-defined hardware enables Moku products to be dynamically reconfigurable in the field, serving a wide range of ever-changing experimental and process control situations. Moku:Lab is used by hundreds of top R&D institutions worldwide, and brings 12+ high-value instruments together into a compact, intuitive device that has greatly streamlined experimental workflows. For more information, please visit https://liquidinstruments.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom